hepatitis C

The Five Best-Performing Biotech Stocks of 2011 -- So Far

Pharmaceuticals are facing big patent cliff problems this year, but several biotechnology stocks have been doing quite well: Their biologic drugs command high prices, tend become blockbusters, and -- perhaps most important -- are in far less danger from generic competition. Here are the big winners so far.

Growing Interest
in Achillion's Hepatitis Drugs

At a liver disease conference in Boston, one of the highlights is expected to be reports from Achillion about its novel hepatitis C treatments, especially ACH-1625. The buzz is growing stronger that the little biotech is attracting the attention of some players in Big Pharma.

Novartis Halts Two Drug Development Programs

Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs -- the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of approximately $590 million in third quarter of 2010.

Achillion's 'Very Promising' Drug for Hepatitis C

Viral hepatitis is the leading cause of liver cancer and the most common reason for a liver transplant. Currently, few therapeutic options exist, but Achillion is hotly pursuing a "protease inhibitor" that can block the hepatitis C virus's action.